AbbVie

CytRx Corporation is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. RNAi has been shown to effectively silence a targeted disease-causing gene within a living cell. The technology uses ribonucleic acid to selectively turn off the harmful genes of infectious viruses or malignant tumor cells. The company s small molecule drug candidates provide cellular protection by activating molecular chaperone proteins that can repair or degrade proteins that are believed to cause many diseases. The company s research and development activities are focused on two of its technologies, FLOCOR, an intravenous agent for acute vaso-occlusive disorders and related acute care applications, and TRAXZFECT, a DNA delivery technology which may have wide applications in DNA vaccines and gene therapy. CytRx Corporation is headquartered in Los Angeles.

MannKind Corporation is a biopharmaceutical company that is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. It is in Phase 3 clinical trials of its lead product, the Technosphere Insulin System, in the U.S. and Europe, to study its safety and efficacy in the treatment of diabetes. This therapy consists of a proprietary dry powder Technosphere formulation of insulin that is inhaled into the deep lung using its proprietary MedTone inhaler. The inhaler is light, easy to use and fits in the palm of the patient's hand, which is believed to facilitate patient compliance. The significantly higher bioavailability, and the convenience and ease of use of the Technosphere Insulin System may result in the potential to change the way diabetes is treated. MannKind Corporation is located in Valencia, Calif.

OXiGENE is a pharmaceutical company that develops novel small-molecule therapeutics to treat cancer and eye diseases. The company s major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. The company s flagship compound, Combretastatin CA4 Prodrug, is a cancer treatment based on vascular targeting agents. OXiGENE also evaluates the use of its vascular targeting agents in an ophthalmology setting. Similar to CA4P's ability to target and disrupt abnormal tumor blood vessels, it has been shown in preclinical studies to suppress development and induce regression of the recently formed and abnormal blood vessels that occur in certain eye diseases. OXiGENE maintains its headquarters, laboratory and research and development facilities in Waltham, Mass.